Pharmacopsychiatry 2007; 40 - A096
DOI: 10.1055/s-2007-991771

Olanzapine versus placebo in adolescents with schizophrenia

L Kryshanovskaya 1, C Schulz 2, CJ McDougle 3, JA Frazier 4, RW Dittmann 5, C Robertson-Plouch 1, T Bauer 1, W Xu 1, WV Wang 1, J Carlson 1, M Tohen 1
  • 1Eli Lilly & Co., Indianapolis, IN,USA
  • 2University of Minnesota, Minneapolis, MN, USA
  • 3Indiana University, Indianapolis, IN, USA
  • 4McLean Hospital, Harvard Medical School, Boston, MA, USA
  • 5Univ. of Hamburg
  • 6 Lilly Deutschland, Bad Homburg, Germany

Background: Antipsychotics are prescribed for adolescents with schizophrenia, yet they have not been approved nor systematically investigated in double-blind, placebo-controlled trials. Methods: Adolescents (13–17yrs) with schizophrenia received olanzapine (OLZ, 2.5–20mg/day) or placebo (PLC) in a 6-week double-blind, plac.-controlled trial. LOCF mean changes from baseline-to-endpoint were assessed on the BPRS-C, CGI-S, and PANSS scales. Response was defined as a >/=30% decrease in BPRS-C; CGI-S,

This study was supported by Eli Lilly & Co., Indianapolis, USA